Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a median follow-up of 9.5 years

被引：0
|
作者：
Lisi M. Dredze
Michael Friger
Samuel Ariad
Michael Koretz
Bertha Delgado
Ruthy Shaco-Levy
Margarita Tokar
Michael Bayme
Ravit Agassi
Maia Rosenthal
Victor Dyomin
Olga Belochitski
Shai Libson
Tamar Mizrahi
David B. Geffen
机构：
[1] Ben-Gurion University of the Negev,Faculty of Health Sciences
[2] Soroka University Medical Center,Department of Oncology
[3] Ben-Gurion University of the Negev,Department of Public Health
[4] Soroka Medical Center,Division of Surgery and The Eshkol Breast Center
[5] Soroka University Medical Center,Department of Pathology
[6] Soroka Medical Center,Department of Imaging and The Eshkol Breast Center
来源：
Breast Cancer Research and Treatment | 2022年 / 193卷
关键词：
Neoadjuvant; Doxorubicin-cyclophosphamide; Paclitaxel; Breast cancer; Real-world;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：597 / 612
页数：15
相关论文
共 45 条
  • [31] Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
    Schneeweiss, Andreas
    Michel, Laura L.
    Moebus, Volker
    Tesch, Hans
    Klare, Peter
    Hahnen, Eric
    Denkert, Carsten
    Kast, Karin
    Pohl-Rescigno, Esther
    Hanusch, Claus
    Link, Theresa
    Untch, Michael
    Jackisch, Christian
    Blohmer, Jens-Uwe
    Fasching, Peter A.
    Solbach, Christine
    Schmutzler, Rita K.
    Huober, Jens
    Rhiem, Kerstin
    Nekljudova, Valentina
    Luebbe, Kristina
    Loibl, Sibylle
    EUROPEAN JOURNAL OF CANCER, 2022, 160 : 100 - 111
  • [32] Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials
    H M Earl
    L Hiller
    J A Dunn
    A-L Vallier
    S J Bowden
    S D Jordan
    F Blows
    A Munro
    S Bathers
    R Grieve
    D A Spooner
    R Agrawal
    I Fernando
    A M Brunt
    S M O'Reilly
    S M Crawford
    D W Rea
    P Simmonds
    J L Mansi
    A Stanley
    K McAdam
    L Foster
    R CF Leonard
    C J Twelves
    D Cameron
    J MS Bartlett
    P Pharoah
    E Provenzano
    C Caldas
    C J Poole
    British Journal of Cancer, 2012, 107 : 1257 - 1267
  • [33] Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials
    Earl, H. M.
    Hiller, L.
    Dunn, J. A.
    Vallier, A-L
    Bowden, S. J.
    Jordan, S. D.
    Blows, F.
    Munro, A.
    Bathers, S.
    Grieve, R.
    Spooner, D. A.
    Agrawal, R.
    Fernando, I.
    Brunt, A. M.
    O'Reilly, S. M.
    Crawford, S. M.
    Rea, D. W.
    Simmonds, P.
    Mansi, J. L.
    Stanley, A.
    McAdam, K.
    Foster, L.
    Leonard, R. C. F.
    Twelves, C. J.
    Cameron, D.
    Bartlett, J. M. S.
    Pharoah, P.
    Provenzano, E.
    Caldas, C.
    Poole, C. J.
    BRITISH JOURNAL OF CANCER, 2012, 107 (08) : 1257 - 1267
  • [34] Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up)
    Icli, Fikri
    Akbulut, Hakan
    Onur, Handan
    Yalcin, Bulent
    Demirkazik, Ahmet
    Senler, Filiz Cay
    BREAST, 2011, 20 (02): : 155 - 157
  • [35] Breast-Conservative Surgery With and Without Radiotherapy in Patients Aged 55–75 Years With Early-Stage Breast Cancer: A Prospective, Randomized, Multicenter Trial Analysis After 108 Months of Median Follow-up
    C. Tinterri
    W. Gatzemeier
    A. Costa
    M. A. Gentilini
    V. Zanini
    L. Regolo
    C. Pedrazzoli
    E. Rondini
    C. Amanti
    G. Gentile
    M. Taffurelli
    P. Fenaroli
    C. Tondini
    G. Sacchetto
    P. Sismondi
    R. Murgo
    M. Orlandi
    E. Cianchetti
    C. Andreoli
    Annals of Surgical Oncology, 2014, 21 : 408 - 415
  • [36] Breast-Conservative Surgery With and Without Radiotherapy in Patients Aged 55-75 Years With Early-Stage Breast Cancer: A Prospective, Randomized, Multicenter Trial Analysis After 108 Months of Median Follow-up
    Tinterri, C.
    Gatzemeier, W.
    Costa, A.
    Gentilini, M. A.
    Zanini, V.
    Regolo, L.
    Pedrazzoli, C.
    Rondini, E.
    Amanti, C.
    Gentile, G.
    Taffurelli, M.
    Fenaroli, P.
    Tondini, C.
    Sacchetto, G.
    Sismondi, P.
    Murgo, R.
    Orlandi, M.
    Cianchetti, E.
    Andreoli, C.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (02) : 408 - 415
  • [37] Incidence and natural course of CT-detected pulmonary ground-glass nodules in Chinese women with breast cancer: a retrospective, single-center, long-term follow-up study in 4682 consecutive patients
    Xu, Hai
    Pu, Xue-Hui
    Yu, Tong-Fu
    Shi, Hai-Bin
    Wu, Yan-Ling
    Xu, Yi-Ming
    Feng, Qing
    ACTA RADIOLOGICA, 2020, 61 (02) : 175 - 183
  • [38] Reply: “Patients treated with neoadjuvant chemotherapy + radical surgery + adjuvant chemotherapy in locally advanced cervical cancer: long-term outcomes, survival and prognostic factors in a single-center 10-years follow-up”
    D. Luvero
    F. Plotti
    R. Angioli
    Medical Oncology, 2017, 34
  • [39] Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel
    Liu, Minetta C.
    Demetri, George D.
    Berry, Donald A.
    Norton, Larry
    Broadwater, Gloria
    Robert, Nicholas J.
    Duggan, David
    Hayes, Daniel F.
    Henderson, I. Craig
    Lyss, Alan
    Hopkins, Judith
    Kaufman, Peter A.
    Marcom, P. Kelly
    Younger, Jerry
    Lin, Nancy
    Tkaczuk, Katherine
    Winer, Eric P.
    Hudis, Clifford A.
    CANCER TREATMENT REVIEWS, 2008, 34 (03) : 223 - 230
  • [40] Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2
    Ganz, Patricia A.
    Romond, Edward H.
    Cecchini, Reena S.
    Rastogi, Priya
    Geyer, Charles E., Jr.
    Swain, Sandra M.
    Jeong, Jong-Hyeon
    Fehrenbacher, Louis
    Gross, Howard M.
    Brufsky, Adam M.
    Flynn, Patrick J.
    Wahl, Tanya A.
    Seay, Thomas E.
    Wade, James L., III
    Biggs, David D.
    Atkins, James N.
    Polikoff, Jonathan
    Zapas, John L.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (35) : 3942 - +
12345